Topical oxatomide

An alternative approach for the treatment of vulvar lichen sclerosus

M. Origoni, D. Ferrari, M. Rossi, F. Gandini, M. Sideri, A. Ferrari

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: The treatment of vulvar lichen sclerosus has greatly improved in recent years, with the introduction of new pharmacological approaches and reconsideration of the traditional ones. Oxatomide is a molecule with both antihistamine and inhibiting activities for the inflammatory response, which may have potential use against this disease. Methods: We enrolled 22 patients affected by vulvar lichen sclerosus in a double-blind, cross-over, controlled trial. They were administered a 5% oxatomide-based gel formulation and a placebo (petrolatum ointment) topically. At the beginning and the end of the investigation the severity and duration of symptoms, clinical appearance and tolerability were recorded. Statistical analysis of data was performed by Fisher's exact test and the Student-Newman-Keuls test. Results: The results indicate that both regimens are significantly correlated with vulvar pruritus improvement and that 5% oxatomide gel has better anti-itching effects compared to the placebo. Other symptoms responded poorly to the treatment. The rate of complete-partial regression of pruritus was significantly higher (P <0.05) in the oxatomide group than in controls, while no significant improvement was obtained neither with oxatomide or with placebo in terms of clinical appearance. Conclusions: These results, adequately confirmed, could suggest the introduction of oxatomide, in selected patients, as an alternative for the treatment of vulvar lichen sclerosus.

Original languageEnglish
Pages (from-to)259-264
Number of pages6
JournalInternational Journal of Gynecology and Obstetrics
Volume55
Issue number3
DOIs
Publication statusPublished - Dec 1996

Fingerprint

oxatomide
Vulvar Lichen Sclerosus
Pruritus
Placebos
Therapeutics
Gels
Petrolatum
Statistical Data Interpretation
Histamine Antagonists
Ointments
Cross-Over Studies
Pharmacology

Keywords

  • Lichen sclerosus
  • Oxatomide
  • Topical treatment
  • Vulva
  • Vulvar dystrophy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Topical oxatomide : An alternative approach for the treatment of vulvar lichen sclerosus. / Origoni, M.; Ferrari, D.; Rossi, M.; Gandini, F.; Sideri, M.; Ferrari, A.

In: International Journal of Gynecology and Obstetrics, Vol. 55, No. 3, 12.1996, p. 259-264.

Research output: Contribution to journalArticle

Origoni, M. ; Ferrari, D. ; Rossi, M. ; Gandini, F. ; Sideri, M. ; Ferrari, A. / Topical oxatomide : An alternative approach for the treatment of vulvar lichen sclerosus. In: International Journal of Gynecology and Obstetrics. 1996 ; Vol. 55, No. 3. pp. 259-264.
@article{207e01f9e2824cfe8c55ca58c3f88401,
title = "Topical oxatomide: An alternative approach for the treatment of vulvar lichen sclerosus",
abstract = "Objective: The treatment of vulvar lichen sclerosus has greatly improved in recent years, with the introduction of new pharmacological approaches and reconsideration of the traditional ones. Oxatomide is a molecule with both antihistamine and inhibiting activities for the inflammatory response, which may have potential use against this disease. Methods: We enrolled 22 patients affected by vulvar lichen sclerosus in a double-blind, cross-over, controlled trial. They were administered a 5{\%} oxatomide-based gel formulation and a placebo (petrolatum ointment) topically. At the beginning and the end of the investigation the severity and duration of symptoms, clinical appearance and tolerability were recorded. Statistical analysis of data was performed by Fisher's exact test and the Student-Newman-Keuls test. Results: The results indicate that both regimens are significantly correlated with vulvar pruritus improvement and that 5{\%} oxatomide gel has better anti-itching effects compared to the placebo. Other symptoms responded poorly to the treatment. The rate of complete-partial regression of pruritus was significantly higher (P <0.05) in the oxatomide group than in controls, while no significant improvement was obtained neither with oxatomide or with placebo in terms of clinical appearance. Conclusions: These results, adequately confirmed, could suggest the introduction of oxatomide, in selected patients, as an alternative for the treatment of vulvar lichen sclerosus.",
keywords = "Lichen sclerosus, Oxatomide, Topical treatment, Vulva, Vulvar dystrophy",
author = "M. Origoni and D. Ferrari and M. Rossi and F. Gandini and M. Sideri and A. Ferrari",
year = "1996",
month = "12",
doi = "10.1016/S0020-7292(96)02768-3",
language = "English",
volume = "55",
pages = "259--264",
journal = "International Journal of Gynecology and Obstetrics",
issn = "0020-7292",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Topical oxatomide

T2 - An alternative approach for the treatment of vulvar lichen sclerosus

AU - Origoni, M.

AU - Ferrari, D.

AU - Rossi, M.

AU - Gandini, F.

AU - Sideri, M.

AU - Ferrari, A.

PY - 1996/12

Y1 - 1996/12

N2 - Objective: The treatment of vulvar lichen sclerosus has greatly improved in recent years, with the introduction of new pharmacological approaches and reconsideration of the traditional ones. Oxatomide is a molecule with both antihistamine and inhibiting activities for the inflammatory response, which may have potential use against this disease. Methods: We enrolled 22 patients affected by vulvar lichen sclerosus in a double-blind, cross-over, controlled trial. They were administered a 5% oxatomide-based gel formulation and a placebo (petrolatum ointment) topically. At the beginning and the end of the investigation the severity and duration of symptoms, clinical appearance and tolerability were recorded. Statistical analysis of data was performed by Fisher's exact test and the Student-Newman-Keuls test. Results: The results indicate that both regimens are significantly correlated with vulvar pruritus improvement and that 5% oxatomide gel has better anti-itching effects compared to the placebo. Other symptoms responded poorly to the treatment. The rate of complete-partial regression of pruritus was significantly higher (P <0.05) in the oxatomide group than in controls, while no significant improvement was obtained neither with oxatomide or with placebo in terms of clinical appearance. Conclusions: These results, adequately confirmed, could suggest the introduction of oxatomide, in selected patients, as an alternative for the treatment of vulvar lichen sclerosus.

AB - Objective: The treatment of vulvar lichen sclerosus has greatly improved in recent years, with the introduction of new pharmacological approaches and reconsideration of the traditional ones. Oxatomide is a molecule with both antihistamine and inhibiting activities for the inflammatory response, which may have potential use against this disease. Methods: We enrolled 22 patients affected by vulvar lichen sclerosus in a double-blind, cross-over, controlled trial. They were administered a 5% oxatomide-based gel formulation and a placebo (petrolatum ointment) topically. At the beginning and the end of the investigation the severity and duration of symptoms, clinical appearance and tolerability were recorded. Statistical analysis of data was performed by Fisher's exact test and the Student-Newman-Keuls test. Results: The results indicate that both regimens are significantly correlated with vulvar pruritus improvement and that 5% oxatomide gel has better anti-itching effects compared to the placebo. Other symptoms responded poorly to the treatment. The rate of complete-partial regression of pruritus was significantly higher (P <0.05) in the oxatomide group than in controls, while no significant improvement was obtained neither with oxatomide or with placebo in terms of clinical appearance. Conclusions: These results, adequately confirmed, could suggest the introduction of oxatomide, in selected patients, as an alternative for the treatment of vulvar lichen sclerosus.

KW - Lichen sclerosus

KW - Oxatomide

KW - Topical treatment

KW - Vulva

KW - Vulvar dystrophy

UR - http://www.scopus.com/inward/record.url?scp=0030475387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030475387&partnerID=8YFLogxK

U2 - 10.1016/S0020-7292(96)02768-3

DO - 10.1016/S0020-7292(96)02768-3

M3 - Article

VL - 55

SP - 259

EP - 264

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

SN - 0020-7292

IS - 3

ER -